Creating the commercial pathway and infrastructure to enable our Starstim Therapy to positively impact the lives of patients living with complex and often debilitating conditions such as drug-resistant focal epilepsy, treatment-resistant major depression, and more.Functions:• Develop commercial strategies to promote Starstim Therapy for patients with drug-resistant focal epilepsy and treatment-resistant major depression.• Establish partnerships with key stakeholders to expand market reach and product adoption.• Lead cross-functional teams to execute go-to-market plans and achieve objectives.

I defined and executed the sales strategies that drive the growth of NeuroPace’s groundbreaking RNS (Responsive Neurostimulation System) for the treatment of drug-resistant Epilepsy, contributing to NeuroPace's $117M IPO in April of 2021.Led a commercial organization of 52 sales and clinical support representatives and 10 sales and clinical managers. Grew sales to record implant, active center, and prescribing epileptologist numbers in 2021-23, with the final quarter of leadership resulting in 63% YOY revenue increase and significant increase in quarterly implant volumeSuccessfully and seamlessly integrated a new exclusive national distributorship for DIXI medical products, doubling sales from 4Q22 to 2Q23 while continuing to grow core RNS businessInstituted an innovative Patient Pipeline Management and sales forecasting system through SFDC that enabled a rigorous territory and regional planning process and drove critical leading KPITransformed the commercial approach of NeuroPace by creating and implementing a comprehensive sales process, with a concurrent Challenger-oriented selling approach and positioning, to spur sales growthSteered the business to double-digit growth in 2020 despite significant Covid disruption.

Recruited to lead the commercial organization (comprised of Sales, Marketing, Training and Medical Education, and Customer Service Departments) of Ceterix Orthopaedics (Acquired by Smith+Nephew), the manufacturer of a disruptive Sports Medicine device that enables Orthopedic Surgeons to repair and preserve the meniscus from injury thought previously non-repairable.The performance resulted in Smith+Nephew's acquisition of the Company for 18x revenues in January 2019. I led the transition to the S+N Sports Medicine organization before taking a new opportunity with an emerging company in the implantable neurostimulation for refractory epilepsy space in June 2019.Transitioned sales team from 3rd party distribution to direct sales, and developed and installed the complete sales process and sales methodology, positioning, etc. to drive success. Re-structured and re-aligned Marketing, enabling a downstream focus inclusive of new digital, education and customer penetration strategies to align with commercial revenue and market expansion goals.www.ceterix.com

Led the global Sales and Marketing departments of Former Lake Region Medical (Acquired by Greatbatch Medical 10/2015 and renamed Integer, 5/16). Responsible for proactively securing intake and negotiation of development and supply agreements for co-development and manufacturing rights of new complete finished devices to strategic cardiovascular customers, and the sale of organically developed guidewires, catheters and introducers, for major strategic distribution.• Created the Business Acceleration Plan, a new go-to-market strategic plan designed to accelerate sales opportunities through a coordinated R&D capability and market intelligence match, combined with a structured, directed sales execution and customer management plan.• Plan execution fostered pipeline growth from $20M to $145M in projected annual manufacturing• Garnered over 70% of pipeline from more profitable and advanced catheter or system based devices, consistent with strategic growth direction.• Restructured department to strengthen sales team and create dedicated international, upstream and downstream marketing units.• Full P&L responsibility for Product Solutions inclusive or Sales, Marketing and R&D budget formulations, NRE and NPI Revenue and EBITDA.

Reported to CEO, recruited as VP Sales into the organization by the Board Chairman to lead the U.S. Sales and Customer Service organizations of the manufacturer of the first Neuromodulation and Medical Device-based therapy for the treatment of Major Depression within the emerging private practice psychiatry market. • Introduced new sales processes, teams and marketing programs that grew disposable unit sales by 46% in 2012 and 30% in 2013 across the board and an average of 33% increased utilization in individual pre-existing accounts utilizing these programs. Sales grew from 86,000 units annually in 2011 to 165,000 units annually by 2013 continuing to grow in 2014.• Streamlined the order to cash process and communication between sales, customer support and operations resulting in increased efficiencies and gaining an additional 7 days for sales capital closes at quarter end• Spearheaded effort to improve web front end enabling increased online ordering and reducing customer service manual processes.• Implemented a customer rebate program in 2013 that successfully prevented a new low cost competitor from establishing a foothold in the market. • Provided new developmental and promotional pathways for sales and customer service teams including additional roles of Strategic Accounts Manager, Director of Practice Development and Territory Manager.

All positions with VNUS Medical and Covidien. VNUS Medical NASDAQ IPO 2004, acquired by Covidien 2009: $440M (net of cash - $500M tot.). Covidien was acquired by Medtronic in 2015.VP of Sales, 2007-2011Director of Sales, 2005-2007Regional Sales Manager, 2002-2005Territory Sales Manager, 2001Promoted 2007 to VP Sales to lead U.S. Sales and Customer Service organization of VNUS Medical Technologies, Inc. , the manufacturer of the first Rf ablation catheter system for the treatment of Venous Reflux Disease, the root cause of varicose veins. VNUS' disruptive technology changed the treatment paradigm and created the market for saphenous vein ablation. In this role, I doubled sales and successfully led the organization to acquisition by Covidien, staying on board to establish its success within the newly created Vascular Therapies division. • More than doubled sales during tenure from $49M FY2006 to $109M FY2010. • Surpassed guidance 11 straight quarters as a public company through completion of acquisition.• Averaged 23% revenue growth per year as VP Sales from 2007-2010, and exceeded publicly reported annual plan targets every year through acquisition.• Successfully guided launch of flagship ClosureFast device (CLF) to 100% conversion by customer base.• Post launch of CLF, Conceived of and implemented the Practice Marketing Roadmap, increased market share to 67% and added over 400 competitive accounts. • Achieved operational efficiencies by automating customer service functions, overseeing development of sales operations and sales analytics teams. • Identified and penetrated Interventional Cardiology as a new market, now core Covidien strategy.• Guided organization through Covidien transition continuing to exceed sales targets through FY10.• Completed Covidien’s ASPIRE Experienced Leader (3/10-8/10) exclusive executive development program.• Instituted several developmental training programs and promotional pathways for sales team for retention.

Directed the majority of the U.S. Sales organization of VNUS. Four of then 5 regions reported directly to me.• Grew sales despite customer base erosion caused by new low cost competitors and aging flagship product (replaced in 2007).• Hired / promoted 6 regional managers during directorship and created one expansion region. • Promoted to Vice President of Sales in 2007.

Here I led the Midwest Region team for VNUS. Originally led the northern half of the country as one of first two Regional Managers with 11 direct reports, eventually running a more traditional Midwest footprint as our success led to expansion of the sales organization.• Won Region of the Year 2003 and 2004. Promoted to Director of Sales 2005• Delivered 13 straight quarters of over quota performance prior to promotion to Sales Director.• Several of my direct reports became national award winners. Two promoted to Regional Manager.

Introduced and expanded sales throughout a 5 state area based in MN.•Attained most new customers in country in first calendar year (17 in 9 mo. of tenure).•Personally sold compay's first business in Mayo Clinic in both Vascular and Dermatology Surgery.•Promoted to RSM after 10 months.

Expanded InnerDyne's base of business with the Step(tm) family of laparoscopic access devices in Minneapolis and outstate Minnesota (selling primarily against Johnson & Johnson and U.S. Surgical contracts), in addition to field training independent, distributor and direct representatives in the Midwest Region. •Increased 1999 sales by 11% over 1998 in only nine full months with the company and Established 19 new hospital accounts, including the University of Minnesota. •InnerDyne was acquired by Tyco/Covidien in 2001

Product Specialist, Ft. Lauderdale, FL 1993-1996 Regional Manager, Ft. Lauderdale, FL 1994-1996 National Sales Manager 1996 - 1999I managed and directed the domestic sales force of the Plastic Surgery Division. Responsibilities included: increasing divisional sales; hiring all sales representatives; establishing all sales quotas; coordinating bids and directly handling or assisting senior field representatives with major accounts. In addition I created, standardized and implemented all in-house product and sales skills training.•Led sales team to 28% growth and record yearly revenues in 1998.•Standardized main product line to streamline production, shorten delivery dates, improve corporate credibility with customers, and increase sales.•Formulated and executed full-scale sales analysis to track individual rep and product sales, spot trends, and identify product cycles in order to increase sales force effectiveness.